Pee on a Stick, Save Your Bones, and Sleep Apnea's Hidden Threat

Episode Script

Thanks Toni. We've got a genuinely interesting mix today — some things that are useful right now, some things that are years away, and one thing that I think a lot of women in perimenopause are completely missing.

Let's start with the hormone monitoring study, because it came out today and it raises a question I find worth sitting with.

The paper is from researcher K.R. Hirsch, published September 8th, 2026, in PubMed. The title is a mouthful, but the concept is fairly simple: can tracking your hormones daily through urine — at home, not in a lab — actually tell you something useful about your health, your nutrition, and how you should be exercising? The study uses illustrative cases, meaning real women's hormone data is used to show patterns and make points. It's not a randomized controlled trial. It's not even close to that.

So right away I want to be clear about what this paper is and isn't. It is a case-based perspective piece. That means it's researchers saying "look at these interesting patterns we found in these individual women." It is not researchers saying "we tested this on five hundred women and here's what happened." Those are very different things, and a lot of health coverage blurs that line.

That said — the underlying idea is not nothing.

Here's the actual interesting part. Standard hormone testing, the kind your doctor orders, is typically a single blood draw, maybe twice a year if you're lucky. The problem is that hormones during perimenopause are not stable. Estrogen especially can swing wildly from one week to the next, sometimes from one day to the next. A single snapshot might catch you on a high day. Or a low day. Either way, you're making decisions — about symptoms, about treatment, about lifestyle — based on one data point from a system that is actively fluctuating.

Daily urine monitoring, if it works the way this paper suggests, gives you a trend line instead of a snapshot. You can see: my estrogen tanked for twelve days, then spiked, and that lines up with when my sleep fell apart. Or: my progesterone dropped earlier in my cycle than it used to, and that's new. That kind of pattern recognition is genuinely harder to get from a biannual blood draw.

The devices being used for this kind of tracking — and there are a few on the market now — have mostly been built for fertility tracking. The research on their accuracy for fertility is reasonably solid. The research on their usefulness specifically for perimenopause health decisions is much thinner. This paper is one of the first to seriously argue for expanding the use case, and it does that through case examples, not through a clinical trial.

My actual position on this: the concept has real promise, and I'm not dismissing it. But I'm also not going to tell you to go spend money on a daily hormone monitoring device based on a case-based perspective paper, because we don't yet have the evidence that acting on that data leads to better outcomes. The interesting question — does knowing this day-to-day information help women make better decisions about their health — is genuinely unanswered. I hope someone runs that trial, because it's worth knowing.

If you already have access to this kind of monitoring, or you're curious about it, it's worth discussing with a provider who knows how to interpret hormone patterns. Just know that right now, the evidence is at the "interesting signal" stage, not the "proven useful" stage.

---

The bone study is a completely different kind of story. This one is about a drug — not a device, not a supplement — a drug called CADD522. Published September 7th by researcher A. Ersek.

CADD522 works by blocking something called RUNX2, which is a protein that plays a role in how bone cells behave. In post-menopausal bone loss, the balance between cells that build bone and cells that break it down gets disrupted. RUNX2, when it's overactive, can push things in the wrong direction. CADD522 is designed to put the brakes on that.

In the study, it improved bone structure — meaning the actual architecture of the bone, not just the overall density — and it also improved lipid metabolism, which is basically how the body handles fats. That second finding is notable because bone thinning and worsening cholesterol both tend to happen after menopause, and most treatments only target one of them.

Now. This is an animal study. I want to be very direct about that. The results are from mice, not from women. That matters enormously, because a significant number of drugs that look promising in animal models do not translate when tested in humans. We have decades of that history in medicine.

CADD522 is not available to patients. It is not in late-stage human trials as of today. It is a research compound showing a genuinely interesting mechanism. That's the honest description.

Why mention it at all, then? Because the mechanism — targeting bone cell behavior at this particular protein level — is a different approach than what's currently on the market. Most existing treatments for bone thinning work by slowing bone breakdown. CADD522 is working on a different part of the system. If it does translate to humans and it does hold up in trials, it could be meaningful for women who can't use or don't respond to existing options.

The researchers themselves are being appropriately cautious in how they frame this, which I appreciate. The news coverage of it has been a bit breathless, and I understand the instinct — it is an interesting result — but we are at the "maybe this leads somewhere" stage, not the "new treatment is coming" stage.

Worth knowing about. Not worth getting excited about yet.

---

The third item is the one I keep thinking about, and I want to spend some real time on it because I think it is genuinely underappreciated.

This is a review paper — published by Pan JB — on sleep apnea during perimenopause and its connection to cognitive function. Specifically, how sleep apnea presents differently in perimenopausal women, and what the research shows about what it does to the brain.

Sleep apnea is a condition where you stop breathing repeatedly during sleep. Usually multiple times an hour, sometimes more. The standard picture most people have is a middle-aged man, overweight, snoring loudly. That picture is not wrong, but it is incomplete. And the incomplete part is costing women.

Women with sleep apnea tend to present differently. Less dramatic snoring. More insomnia. More fatigue. More mood disruption. More of what looks like anxiety or depression. During perimenopause, all of those things are already on the table as possible symptoms, which means sleep apnea can hide in plain sight. Your doctor is looking at your hot flashes and your irritability and your exhaustion and might reasonably attribute all of it to perimenopause — without ever asking whether you're actually stopping breathing at night.

This review paper looks at the polysomnographic data — polysomnography is just the clinical sleep study, the one where you spend the night with sensors tracking your breathing, brain waves, and oxygen levels — and examines what it shows specifically in perimenopausal women. The data suggests that the breathing disruptions in this group are associated with measurable changes in cognitive function. Memory. Processing speed. Attention. The stuff that often gets called brain fog.

Now I want to be precise here, because this matters. Observational research — which is what most of the sleep apnea and cognition studies are — shows an association. Women with more severe sleep apnea have worse cognitive scores. That is real and consistently replicated. It does not prove that the sleep apnea is causing the cognitive decline. There could be other factors. There could be confounding. What it does tell us is that the link is strong enough, and consistent enough across enough studies, to take seriously.

Here's what I think is worth sitting with: sleep apnea is treatable. CPAP is not glamorous, but it works. There are also other options for people who can't tolerate CPAP — positional therapy, oral appliances, newer surgical options in some cases. This is not a condition you discover and then just live with.

And the symptoms — the fatigue, the brain fog, the waking at night, the mood disruption — those are symptoms that perimenopausal women are commonly told are just part of the transition. Sometimes they are. And sometimes there is something else going on that a doctor who isn't specifically looking for it will miss.

If you are in perimenopause and you are struggling with sleep, with energy, with cognitive sharpness — and especially if anyone has ever mentioned that you snore, or if you wake up unrefreshed no matter how many hours you sleep — sleep apnea is worth raising explicitly with your doctor. Not "I'm tired," but "I want to rule out sleep apnea." A sleep study is the way to do that, and it's covered by most insurance when there's clinical reason for it.

The research on what untreated sleep apnea does to the brain over time is not reassuring. And the research on what treating it can do — including for cognitive function — is considerably more encouraging.

---

Sources curated automatically by the Hot Flasher pipeline.